Literature DB >> 32409867

Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD).

John B Buse1, Deborah J Wexler2,3, Apostolos Tsapas4, Peter Rossing5,6, Geltrude Mingrone7,8,9, Chantal Mathieu10, David A D'Alessio11, Melanie J Davies12.   

Abstract

The incorrect figure legend was printed for Fig. 2.

Entities:  

Year:  2020        PMID： 32409867     DOI： 10.1007/s00125-020-05151-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


  4 in total

Review 1.  Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.

Authors:  Luis D'Marco; María Jesús Puchades; Lorena Gandía; Claudia Forquet; Elena Giménez-Civera; Nayara Panizo; Javier Reque; Isabel Juan-García; Valmore Bermúdez; José Luis Gorriz
Journal:  touchREV Endocrinol       Date:  2021-11-10

2.  A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population.

Authors:  Lianglan Shen; Hongli Yang; Xingxing Fang; Huaxing Huang; Wubin Yao; Dongmei Chen; Yan Shen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-13       Impact factor: 3.168

3.  Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study.

Authors:  György Rokszin; Zoltán Kiss; Gábor Sütő; Péter Kempler; György Jermendy; Ibolya Fábián; Zoltán Szekanecz; Gyula Poór; István Wittmann; Gergő Attila Molnár
Journal:  Front Oncol       Date:  2021-10-28       Impact factor: 6.244

4.  Perceptions about the Management of Patients with DM2 and COVID-19 in the Hospital Care Setting.

Authors:  Ricardo Gómez-Huelgas; Fernando Gómez-Peralta
Journal:  J Clin Med       Date:  2022-08-02       Impact factor: 4.964
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.